{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:49:07Z","timestamp":1792158547624,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Infectious Diseases Society of America 2020 guidelines recommend Bayesian-guided area under the curve (AUC) monitoring for vancomycin dosing in pediatric patients. Our institution\u2019s neonatal intensive care unit (NICU) utilizes single-level kinetics to monitor AUC using 2 pharmacokinetic models validated in neonates and infants. Anecdotally, preterm infants corrected to a higher postmenstrual age (PMA) may be better suited to the pediatric dosing model (PDM) versus the neonatal dosing model (NDM). This study aims to identify which model is best suited to the NICU population based on factors including gestational age (GA), postnatal age (PNA), and PMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review including 64 NICU patients who received vancomycin was conducted. Measured vancomycin trough concentrations were compared to Bayesian model predictions using both the NDM and PDM. Model performance was evaluated using median absolute prediction error and stratified by GA, PNA, and PMA. Predicted AUC and pharmacokinetic parameters were also compared between models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PDM had greater predictive accuracy and less variability in trough concentrations across GA and PNA groups when compared to the NDM. Stratified analysis showed that the PDM was most accurate in term infants and those with a PMA of &amp;lt;29 or &amp;gt;52 weeks. The NDM consistently overpredicted trough levels in extremely preterm and early postnatal infants, leading to larger AUC discrepancies. Alternative models may improve predictive performance, particularly in high-risk neonatal subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PDM had superior predictive performance when compared to the NDM. Use of the PDM may improve vancomycin dosing accuracy in NICU patients, especially those with more advanced PMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag313","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:38:20Z","timestamp":1790275100000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of vancomycin Bayesian dose-optimizing software in a neonatal intensive care unit population"],"prefix":"10.1093","author":[{"given":"Chelsey","family":"Ivy","sequence":"first","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Ball","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"McTish","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Hemmann","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"4","key":"2026101609010799600_zxag313-B1","doi-asserted-by":"publisher","first-page":"106958","DOI":"10.1016\/j.ijantimicag.2023.106958","article-title":"Association between vancomycin therapeutic drug monitoring and clinical outcomes in treating neonatal sepsis","volume":"62","author":"Chung","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2026101609010799600_zxag313-B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S2352-4642(21)00305-9","article-title":"Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial","volume":"6","author":"Hill","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"2026101609010799600_zxag313-B3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13063-020-4184-8","article-title":"An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to gram-positive microorganisms in neonates and infants aged less than 90","volume":"21","author":"Hill","year":"2020","journal-title":"Trials"},{"issue":"6","key":"2026101609010799600_zxag313-B4","doi-asserted-by":"publisher","first-page":"e2022058813","DOI":"10.1542\/peds.2022-058813","article-title":"Late-onset sepsis among very preterm infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics"},{"issue":"5","key":"2026101609010799600_zxag313-B5","doi-asserted-by":"publisher","first-page":"e2021052360","DOI":"10.1542\/peds.2021-052360","article-title":"Safety and efficacy of nafcillin for empiric therapy of late-onset sepsis in the NICU","volume":"149","author":"Magers","year":"2022","journal-title":"Pediatrics"},{"issue":"8","key":"2026101609010799600_zxag313-B6","doi-asserted-by":"publisher","first-page":"e0306855","DOI":"10.1371\/journal.pone.0306855","article-title":"Neonatal bacteraemia in Ireland: a ten-year single-institution retrospective review","volume":"19","author":"Powell","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"2026101609010799600_zxag313-B7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2026101609010799600_zxag313-B8","doi-asserted-by":"publisher","first-page":"106958","DOI":"10.1016\/j.ijantimicag.2023.106958","article-title":"Association between vancomycin therapeutic drug monitoring and clinical outcomes in treating neonatal sepsis","volume":"62","author":"Chung","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2026101609010799600_zxag313-B9","doi-asserted-by":"publisher","first-page":"e0189921","DOI":"10.1128\/aac.01899-21","article-title":"Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling","volume":"66","author":"Jarugula","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2026101609010799600_zxag313-B10","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1128\/AAC.03620-14","article-title":"Association between vancomycin trough concentration and area under the concentration-time curve in neonates","volume":"58","author":"Frymoyer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2026101609010799600_zxag313-B11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.4623","article-title":"External evaluation of neonatal vancomycin population pharmacokinetic models: moving from first-order equations to Bayesian-guided therapeutic monitoring","volume":"44","author":"Blouin","year":"2024","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2026101609010799600_zxag313-B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/AAC.44.2.278-282.2000","article-title":"A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population","volume":"44","author":"Lamarre","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026101609010799600_zxag313-B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.siny.2012.10.003","article-title":"Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration","volume":"18","author":"Jacqz-Aigrain","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"issue":"6","key":"2026101609010799600_zxag313-B14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.5863\/1551-6776-25.6.476","article-title":"Challenges of vancomycin dosing and therapeutic monitoring in neonates","volume":"25","author":"Pham","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"2026101609010799600_zxag313-B15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-2125.2010.03736.x","article-title":"Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline","volume":"70","author":"Marques-Minana","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2026101609010799600_zxag313-B16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40262-024-01353-8=","article-title":"Bayesian vancomycin model selection for therapeutic drug monitoring in neonates","volume":"63","author":"Alrahahleh","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026101609010799600_zxag313-B17","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1038\/s41598-021-85529-3","article-title":"Population pharmacokinetics and dose optimization of vancomycin in neonates","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"2026101609010799600_zxag313-B18","doi-asserted-by":"publisher","first-page":"104278","DOI":"10.1016\/j.phrs.2019.104278","article-title":"Optimisation of vancomycin exposure in neonates based on the best level of evidence","volume":"154","author":"Dao","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"2026101609010799600_zxag313-B19","doi-asserted-by":"publisher","first-page":"e0159123","DOI":"10.1128\/aac.01591-23","article-title":"Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates","volume":"68","author":"Kalamees","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026101609010799600_zxag313-B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40262-022-01185-4","article-title":"Evaluation of neonatal and paediatric vancomycin pharmacokinetic models and the impact of maturation and serum creatinine covariates in a large multicentre data set","volume":"62","author":"Hughes","year":"2023","journal-title":"Clin Pharmacokinet"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag313\/71383479\/zxag313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag313\/71383479\/zxag313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:01:14Z","timestamp":1792155674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag313\/8833988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag313","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"zxag313"}}